| Summary: | Gliclazide is used in Type 2 diabetes (T2D) to stimulate insulin production but it also has beneficial extra-pancreatic effects which make it potentially useful in T1D. In this thesis, gliclazide was formulated with different bile acids, to enhance its effects, and formed microcapsules were examined in-vitro and in-vivo. In-vitro examinations of the microcapsules included complete characterization of the microcapsules in terms of interactions between gliclazide and a primary bile acid (chenodeoxycholic acid), a secondary bile acid (taurocholic acid) and a tertiary bile acid (ursodeoxycholic acid), and in-vitro release of gliclazide from microcapsules, while in-vivo examination of the microcapsules included gliclazide absorption and hypoglycemic and antiinflammatory effects in a rat model of T1D.
|
|---|